الفهرس | Only 14 pages are availabe for public view |
Abstract Cardiomyopathies comprise a heterogeneous group of diseases with myocardial disorders that are linked to cardiac structural and functional abnormalities, often resulting in sudden cardiac death or progressive heart failure. It has been reported that hypertrophic cardiomyopathy (HCM) is the most common cause of sudden cardiac death among the young population (1). Hypertrophic cardiomyopathy (HCM), the most common inherited cardiomyopathy with an approximate prevalence of one in 500, it represents one of the most fascinating diseases in cardiovascular medicine, attracting he interest of physicians, geneticists, and scientists worldwide. This disorder is characterized by inappropriate myocardial hypertrophy occurring in the absence of any detectable cardiac or systemic cause, such as aortic stenosis, patients with HCM may experience life-threatening cardiovascular events. Sudden cardiac death (SCD) accounts for approximately 51% of cardiovascular events in HCM, followed by heart failure (36%) and stroke (13%) (2, 3). Myocardial fibrosis is the pathological hallmark of hypertrophic cardiomyopathy. Myocardial fibrosis may result in myocardial stiffness and dysfunction, ultimately leading to the progression of heart failure and adverse clinical outcomes. Therefore, detecting and quantifying myocardial fibrosis may improve risk stratification and contribute to clinical therapies and prognostic stratification for hypertrophic cardiomyopathy patients (4). The most common method of diagnosing HCM is echocardiography. |